In the final week of July 2017, the FDA issued a notification that it had approved a revised drug label for Invokana and Invokamet, as well as a revised Medication Guide for these two diabetes drugs from Janssen Pharmaceuticals. From the most recent drug label, or Full Prescribing Information, for Invokana (accessed 7/27/17), here is the text of … [Read more...]
Birth Control Pills Series: Are the Current FDA Label Warnings Enough?
In the previous article of my blog series on Yaz, Yasmin, Ocella, Gianvi, Safyral, and Beyaz, I discussed the devastating side effects that can result from using these DRSP-containing birth control pills. For my final article in this series, I will discuss the current drug label warnings for these drugs, and contemplate whether these warnings … [Read more...]
Birth Control Pills Series: The Devastating Side Effects
The first article of my blog series on Yaz, Yasmin, Ocella, Gianvi, Safyral, and Beyaz discussed how Yaz in particular was marketed to treat premenstrual dysphoric disorder (PMDD)--before PMDD was even classified as a medical condition--so that the drug manufacturer, Bayer, could increase their profits. In this article, I will provide … [Read more...]